Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Dr Aldoss on the Mechanism of Action of Ponatinib in Ph+ ALL

April 29th 2024

Ibrahim Aldoss, MD, discusses the use of ponatinib as evaluated in the PhALLCON trial for patients with Ph+ ALL.

Dr Fedorov on the Use of Quizartinib vs Midostaurin in FLT3+ AML

April 26th 2024

Kateryna Fedorov, MD, discusses considerations when deciding between quizartinib and midostaurin for patients with FLT3-mutated AML.

Dr Pantin on the Evolving Treatment Paradigm in PNH

April 25th 2024

Jeremy M. Pantin, MD, discusses the evolution of the PNH treatment paradigm and agents that are available or being investigated in this disease.

Dr Annie Im: How to Treat Acute Myeloid Leukemia in 2024

April 25th 2024

Annie Im, MD, FASCO, University of Pittsburgh/UPMC Hillman Cancer Center, discusses the various modern approaches for the treatment of patients with acute myeloid leukemia.

ODAC Decisions Confirm Benefit of Ide-Cel and Cilta-Cel in Earlier Line R/R Myeloma Therapy

April 25th 2024

Kenneth C. Anderson, MD, discusses the recent ODAC decisions for ide-cel and cilta-cel, highlighting clinical trial data supporting the indications.

CD7 CAR T-Cell Therapy Plus Allogeneic HSCT Is Safe, Feasible in CD7+ Hematologic Malignancies

April 24th 2024

Sequential CD7 CAR T-cell therapy plus haploidentical HSCT without GVHD prophylaxis is effective and safe in CD7-positive hematologic malignancies.

Dr Ignatz-Hoover on the Evolving Use of Blinatumomab in ALL

April 24th 2024

James Ignatz-Hoover, MD, PhD, discusses the implications of utilizing blinatumomab to treat acute lymphoblastic leukemia.

Dr Marc Braunstein: Program Building, Education in Hematologic Cancers

April 23rd 2024

Marc J. Braunstein, MD, PhD, FACP, of NYU Grossman Long Island School of Medicine, discusses lessons learned with program building and medical education with hematologic cancers.

Dr Coombs on the Ongoing Investigation of Quizartinib in AML

April 22nd 2024

Catherine C. Coombs, MD, discusses the efficacy of the FLT3 inhibitor quizartinib in acute myeloid leukemia.

FDA Grants Breakthrough Therapy Designation to Ziftomenib in NPM1-Mutant AML

April 22nd 2024

The FDA has granted breakthrough therapy designation to ziftomenib for the treatment of NPM1-mutant acute myeloid leukemia.

FAK Inhibition Emerges as a Potential Complementary Treatment Pathway

April 22nd 2024

Although FAK inhibition alone has displayed modest activity to date, there is interest in developing FAK-targeted therapies for combination regimens.

Dr Castillo on the Rationale for Evaluating Iopofosine I 131 in Waldenström Macroglobulinemia

April 19th 2024

Jorge J. Castillo, MD, discusses the rationale for evaluating the iopofosine I 131 in Waldenström macroglobulinemia.

Revisit Every OncLive On Air Episode from March 2024

April 19th 2024

In case you missed any, below is a recap of every episode of OncLive On Air that aired in March 2024.

FDA Requires Boxed Warning for Risk of T-Cell Malignancies With Approved CAR T-Cell Therapies

April 19th 2024

The FDA has mandated that the boxed warning for all approved CAR T-cell therapies be updated to include the serious risk of T-cell malignancies.

Dr Coombs on Disease Management Strategies in AML

April 18th 2024

Catherine C. Coombs, MD, discusses strategies for disease classification and management for patients with acute myeloid leukemia.

Call for Boxed Warning for Secondary Malignancies on CAR T-Cell Therapies Raises Alarm, But Key Questions Remain

April 18th 2024

Experts discuss the FDA's call for a boxed warning for secondary T-cell malignancies on all approved CAR T-cell agents in late January 2024.

EMA Grants Orphan Drug Designation to Annamycin in AML

April 18th 2024

The European Medicines Agency has granted orphan drug designation to annamycin for the treatment of patients with acute myeloid leukemia.

Belumosudil Produces Long-Term Responses Without New Safety Concerns in cGVHD

April 17th 2024

Belumosudil elicited sustained responses and generated no new safety signals in patients with chronic graft-vs-host disease.

FDA Grants Orphan Drug Designation to BVX001 in AML

April 17th 2024

BVX001 has received orphan drug designation from the FDA for the treatment of patients with acute myeloid leukemia.

Prophylactic Itacitinib May Safely Mitigate CRS Following Axi-Cel Administration in Lymphoma

April 16th 2024

Itacitinib prophylaxis showed signals for reducing CRS and ICANS following treatment with axicabtagene ciloleucel in patients with B-cell lymphoma.